


Chemoenzymatic Total Syntheses of the Enantiomers of the Protoilludanes 8-Deoxydihydratsugicoline and Radudiol

Ee Ling Chang, Benoit Bolte, Ping Lan, Anthony C. Willis, and Martin G. Banwell*

Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, ACT 2601, Australia

S Supporting Information

ABSTRACT: Chemoenzymatic and stereoselective total syntheses of the non-natural enantiomeric forms of the recently isolated protoilludane natural products 8-deoxydihydratsugicoline (**1**) and radudiol (**2**) (viz. *ent*-**1** and *ent*-**2**, respectively) are reported. The key steps involve the Diels–Alder cycloaddition of cyclopent-2-en-1-one to the acetonide derived from enantiomerically pure and enzymatically derived *cis*-1,2-dihydrocatechol **3**, elaboration of the resulting adduct to the tricyclic ketone **12**, and a photochemically promoted rearrangement of this last compound to the octahydro-1*H*-cyclobuta[*e*]indenone **13**.



INTRODUCTION

Protoilludane-type sesquiterpenoids embody the distinctive perhydro-1*H*-cyclobuta[*e*]indene or 5/6/4 tricyclic framework and are produced by a range of higher-order fungi via a humulene cyclization pathway.^{1,2} New members of this class continue to be isolated at regular intervals,³ and various interesting biological activities have been attributed to a number of them. These activities include antibacterial, antifungal, cytotoxic, and plant growth-regulating effects.^{1,3,4} On this basis and because of their challenging structural features, they have been the focus of significant and ongoing synthetic efforts.^{1,5} Recently, we disclosed a chemoenzymatic synthesis of the melleolide or protoilludane aryl ester (+)-armillarivin.^{5b} The first of two key chemical steps involved the high-pressure (19 kbar) promoted and facially selective Diels–Alder cycloaddition of an enzymatically derived and enantiomerically pure *cis*-1,2-dihydrocatechol with cyclopent-2-en-1-one. The second step was a photochemically promoted 1,3-acyl migration (Givens rearrangement)⁶ of a derivative of the cycloadduct that afforded the full 5/6/4 tricyclic framework of the target natural product.

Herein, we describe the total syntheses of the enantiomers of 8-deoxydihydratsugicoline (**1**)^{3b} and radudiol (**2**) (viz. *ent*-**1** and *ent*-**2**, respectively)^{3a,d} which are protoilludanes recently isolated from, *inter alia*, *Granulobasidium vellereum* (Ellis & Cragin) Jülich, a saprotrophic and rare wood-decay basidiomycete fungus encountered in deciduous forests throughout East Asia, North America, and Europe (Figure 1). The structures of compounds **1** and **2** were assigned using NMR, MS, CD and polarimetry techniques. The synthetic chemistry studies reported here, which are the first involving the title compounds, serve to confirm the structures of these natural products as well as demonstrate, when considered in conjunction with our earlier work,^{5d} that either enantiomeric form of the perhydro-




Figure 1. Structures of protoilludanes **1** and **2**, their enantiomers, and the metabolite **3** used as the starting material in the present study.

1*H*-cyclobuta[*e*]indene framework can be obtained from the *cis*-1,2-dihydrocatechol **3** by controlling the facial selectivity of the Diels–Alder reaction of this diene and its derivatives with cyclopent-2-en-1-one.


RESULTS AND DISCUSSION

The reaction sequence leading from metabolite **3**⁷ to compounds *ent*-**1** and *ent*-**2** is shown in Scheme 1 and begins with the previously reported⁸ microwave-promoted Diels–Alder cycloaddition of 2-cyclopenten-1-one (**4**) with the acetonide **5**⁹ derived from *cis*-1,2-dihydrocatechol **3**. The

Received: January 8, 2016

Published: February 3, 2016

Scheme 1



adduct obtained (73%) was *gem*-dimethylated by the means described in an earlier report from our group,⁸ and the product so formed (56%) was reduced with LiAlH₄ to produce a ~3:2 mixture of the chromatographically separable and epimeric alcohols **6**⁸ (97%). Each of these was converted into the corresponding methyl xanthate **7** (69–87%) under standard conditions, and a single-crystal X-ray analysis conducted on the β -epimer confirmed their structures (see [Experimental Section](#) and [Supporting Information](#) for details). Barton–McCombie deoxygenation¹⁰ of these esters using *n*-Bu₃SnH in the presence of AIBN produced the anticipated product **8** (87–89%) that, upon treatment with acidified DOWEX-50 resin in aqueous methanol, produced the diol **9** (72%). Selective mono-

oxidation of this last compound to acyloin **10** (90%) could be achieved using the sterically demanding oxoammonium salt derived from the *p*-toluenesulfonic acid-promoted disproportionation of 4-acetamido-TEMPO.¹¹ Compound **10** was converted into the corresponding benzoate **11** (90%), and samarium diiodide-promoted deoxygenation of the latter produced the ketone **12** in 80% yield.

In the second pivotal step of the reaction sequence, a dichloromethane solution of the cyclopentannulated bicyclo[2.2.2]oct-5-en-2-one **12** was subjected to direct irradiation using a medium-pressure mercury vapor lamp, resulting in the anticipated 1,3-acyl migration reaction to produce the cyclobutanone **13** (54% at 51% conversion) that

Table 1. Comparison of the ^{13}C and ^1H NMR Data Recorded for Synthetically Derived Compound *ent-1* with Those Reported for 8-Deoxydihydrotugicolone (1)

^{13}C NMR data for compound 1 (δ_{C}) ^a	^{13}C NMR data for compound <i>ent-1</i> (δ_{C}) ^b	^1H NMR data for compound 1 (δ_{H}) ^c	^1H NMR data for compound <i>ent-1</i> (δ_{H}) ^d
210.7	210.4	3.04, t, $J = 10.5$ Hz, 1H	3.05, t, $J = 10.4$ Hz, 1H
75.4	75.2	3.01, dd, $J = 16.1$ and 2.2 Hz, 1H	3.02, dd, $J = 15.9$ and 2.2 Hz, 1H
71.9	71.8	2.59, dd, $J = 16.1$ and 4.7 Hz, 1H	2.59, dd, $J = 15.9$ and 4.8 Hz, 1H
58.4	58.4	2.52, ddd, $J = 9.7, 4.7,$ and 2.2 Hz, 1H	2.52, ddd, $J = 9.7, 4.8,$ and 2.2 Hz, 1H
48.2	48.1	2.38, dt, $J = 10.6$ and 8.2 Hz, 1H	2.39, dt, $J = 10.6$ and 8.1 Hz, 1H
46.4	46.3	2.06, dddd, $J = 10.5, 8.2, 7.1,$ and 6.8 Hz, 1H	2.06, m, 1H
45.9	45.8	1.69, ddd, $J = 13.1, 7.1,$ and 1.1 Hz, 1H	1.69, dd, $J = 13.2$ and 7.2 Hz, 1H
44.1	44.1	1.62, dd, $J = 13.1$ and 6.8 Hz, 1H	1.66–1.54, complex m, 3H
38.4	38.3	1.60, m, 1H	–
38.0	37.9	1.59, m, 1H	–
31.5	31.5	1.49, dd, $J = 13.0$ and 10.6 Hz, 1H	1.49, dd, $J = 12.9$ and 10.5 Hz, 1H
31.0	31.0(3)	1.23, s, 3H	1.23, s, 3H
31.0	30.9(7)	1.13, s, 3H	1.13, s, 3H
27.2	27.3	1.06, d, $J = 6.5$ Hz, 3H	1.06, d, $J = 6.5$ Hz, 3H
18.4	18.4	1.03, s, 3H	1.03, s, 3H
–	–	signal due to hydroxyl group proton not observed	signal due to hydroxyl group proton not observed

^aData obtained from ref 3b were recorded in CD_3OD at either 150 or 100 MHz. ^bData were recorded in CD_3OD at 100 MHz. ^cData obtained from ref 3b were recorded in CD_3OD at either 600 or 400 MHz. ^dData were recorded in CD_3OD at 400 MHz.

Table 2. Comparison of the ^{13}C and ^1H NMR Data Recorded for Synthetically Derived Compound *ent-2* with Those Reported for Radudiol (2)

^{13}C NMR data for compound 2 (δ_{C}) ^a	^{13}C NMR data for compound <i>ent-2</i> (δ_{C}) ^b	^1H NMR data for compound 2 (δ_{H}) ^c	^1H NMR data for compound <i>ent-2</i> (δ_{H}) ^d
76.3	76.5	3.98, ddd, $J = 7, 7,$ and 7 Hz, 1H	4.01, q, $J = 7.0$ Hz, 1H
71.3	71.8	3.16, dd, $J = 10.8$ and 9.6 Hz, 1H	3.17, dd, $J = 10.9$ and 9.4 Hz, 1H
60.7	61.1	2.36, ddd, $J = 10, 9,$ and 8 Hz, 1H	2.35, dt, $J = 10, 8,$ and 8.5 Hz, 1H
48.0	48.2	2.14, dd, $J = 11.4$ and 7.4 Hz, 1H	2.16, dd, $J = 11.6$ and 7.3 Hz, 1H
46.4	46.4	2.12, dddd, $J = 11, 11, 10,$ and 7 Hz, 1H	2.09, tdd, $J = 11.0, 9.5,$ and 7.0 Hz, 1H
44.6	44.8	1.77, dd, $J = 12.2$ and 6.8 Hz, 1H	1.73, ddd, $J = 12.1, 6.8,$ and 1.5 Hz, 1H
43.7	44.1	1.70, dd, $J = 8$ and 7 Hz, 1H	1.67, t, $J = 7.2$ Hz, 1H
41.2	41.6	1.54, dd, $J = 13.4$ and 9.0 Hz, 1H	1.57–1.34, complex m, 4H
41.4	41.4	1.50, m, 1H	–
38.4	38.7	1.48, dd, $J = 11.4$ and 7.1 Hz, 1H	–
31.0	31.2	1.42, dd, $J = 13.4$ and 8.0 Hz, 1H	–
29.6	29.8	1.25, dd, $J = 12$ and 11 Hz, 1H	1.22, t, $J = 11.9$ Hz, 1H
28.7	28.9	1.11, d, $J = 6.5$ Hz, 3H	1.09, d, $J = 6.4$ Hz, 3H
28.6	28.8	1.12, s, 3H	1.08, s, 3H
18.0	18.1	1.08, s, 3H	1.07, s, 3H
–	–	1.01, s, 3H	0.97, s, 3H
–	–	signal due to hydroxyl group proton not observed	signal due to hydroxyl group proton not observed

^aData obtained from ref 3a were recorded in CDCl_3 at 125 MHz. ^bData were recorded in CDCl_3 at 100 MHz. ^cData obtained from ref 3a were recorded in CDCl_3 at 500 MHz. ^dData were recorded in CDCl_3 at 400 MHz.

embodies the non-natural enantiomeric form of the protoilludane framework.¹² All of the spectroscopic data acquired on compound 13 were in complete accord with the assigned structure. Most notably, the infrared spectrum displayed a carbonyl group absorption band at 1781 cm^{-1} , and the corresponding ^{13}C NMR spectrum showed the expected 14 resonances, including one at δ_{C} 206.4 that is attributed to the carbon of the same moiety. The two lowest field signals appearing at δ_{H} 5.64 and 5.50 in the ^1H NMR spectrum were mutually coupled ($J = 10$ Hz) one-proton multiplets that are assigned to the olefinic protons of the β,γ -unsaturated enone moiety of photoproduct 13.

The elaboration of compound 13 to the target *ent-1* proved to be a straightforward matter that involved, as the first of three steps, treating compound 13 with dimethyldioxirane (DMDO)¹³ which produced a $\sim 3:1$ mixture of the diastereomerically related and chromatographically separable oxiranes 14 (18%) and 15 (57%). Various considerations led to the assigned stereochemistries of these products. First, an inspection of a molecular model of the precursor 13 suggested that the β -face of the olefinic residue is more congested by virtue of the impinging C10 and C11 methyl groups. Furthermore, the ^1H NMR spectrum of the minor product 14 displayed, as expected, a spread of the chemical shifts of the three methyl group singlets (δ_{H} 1.16, 1.09, and 0.99) greater

than that observed in the corresponding spectrum of congener **15** (δ_{H} 1.09, 0.97, and 0.96), wherein the epoxide oxygen is remote from C10 and C11 (see structure **13** for numbering). Further support for these assignments followed from an analysis of the ^1H NMR spectrum of the derived γ -hydroxylated α,β -unsaturated enone **16** that was produced in 56% yield by treating epoxide **15** with lithium hexamethyldisilazide (LiHMDS). In particular, the signal attributed to H4 in the ^1H NMR spectrum of rearrangement product **16** appears as a doublet of doublets ($J = 8.0$ and 2.4 Hz) at δ_{H} 4.13, and the magnitude of the larger coupling is consistent with a relatively large dihedral angle (slightly less than 180°) between this proton and the vicinally related H4a. The 2.4 Hz coupling between the resonances due to H4 and H3 is suggestive of a smaller dihedral angle between these nuclei ($\sim 100^\circ$ as judged by inspection of molecular models) and provides further support for the illustrated α -orientation of the C4 hydroxyl group within allylic alcohol **16**. Final confirmation of the assigned structures of compounds **14**–**16** follows from single-crystal X-ray analyses of each compound. The relevant data are presented in the [Experimental Section](#), and the derived ORTEPs are shown in the [Supporting Information](#).


In the next step of the reaction sequence, enone **16** was reacted with the Gilman reagent¹⁴ generated *in situ* from cuprous iodide and methyllithium, thereby producing *ent*-8-deoxydihydrotsugicoline (*ent*-**1**) in 56% yield. The assigned structure follows from the derived spectral data, and as shown in [Table 1](#), a comparison of the ^{13}C and ^1H NMR data recorded on the synthetic material with those reported^{3b} for the natural product 8-deoxydihydrotsugicoline (**1**) revealed an excellent match. The specific rotation of the synthetically derived material was -24.0 ($c = 2.4$, methanol), while that reported^{3b} for the natural product was $+19$ ($c = 0.13$, methanol), thereby indicating that the two compounds are enantiomerically related.

Reduction of compound *ent*-**1** using sodium bis(2-methoxyethoxy)aluminum hydride afforded a chromatographically separable mixture of the corresponding crystalline cyclobutanols *ent*-radudiol (*ent*-**2**) (41%) and **17** (53%). Single-crystal X-ray analyses were carried out on both of these products, and the derived ORTEPs and selected crystallographic data are provided in the [Supporting Information](#) and [Experimental Section](#), respectively. Once again, a comparison ([Table 2](#)) of the ^{13}C and ^1H NMR data derived from compound *ent*-**2** with those reported^{3a} for the natural product radudiol (**2**) revealed an excellent match.

The specific rotation of the synthetically derived compound *ent*-**2** was -24 ($c = 1.0$, CHCl_3), while that reported^{3a} for the natural product is $+27$ ($c = 1.0$, CHCl_3), thereby indicating that these two compounds are also enantiomerically related.

Methylenecyclobutanone **16** and derivative *ent*-**1** each displayed unanticipated reactivities that are worth noting. As shown in [Scheme 2](#), after treatment of methylenecyclobutanone **16** with the Gilman reagent with the intent of generating the conjugate addition product *ent*-**1**, varying quantities (see [Experimental Section](#)) of the chromatographically separable crystalline heterodimer **18** were also observed. Compound **18**, the structure of which was confirmed by single-crystal X-ray analysis, presumably arises through sequential hetero-Michael–Michael addition reactions of monomer **16**.¹⁵ Cyclobutanone *ent*-**1**, on the other hand, engaged in a regioselective Baeyer–Villiger-type oxidation reaction after exposure to air for an extended period of time, producing lactone **19**. The structure of this last compound was also confirmed by single-crystal X-ray

Scheme 2



analysis. The conversion of *ent*-**1** \rightarrow **19** raises the possibility that the enantiomer of *ent*-**19** could be encountered in extracts of the organism that produces 8-deoxydihydrotsugicoline (**1**).

CONCLUSION

The present work serves to highlight the utility of the readily available, stereochemically defined, and enantiomerically pure metabolite **3** as a starting material in the chemical synthesis of either enantiomeric form of the protoilludane framework. The form that is obtained is dictated by the facial selectivity of the Diels–Alder reaction engaged in by this cyclic diene or its derivatives.¹⁶ Thus, the high-pressure promoted cycloaddition reaction of compound **3** with dienophiles such as cyclopent-2-en-1-one (**4**) results in preferential *syn*-addition (relative to the hydroxyl groups of the diene) and the formation of adducts that can be elaborated to the natural enantiomeric form of the protoilludane framework.^{5b} In contrast, the acetonide derivative **5** of metabolite **3** readily participates in a thermally induced Diels–Alder reaction that proceeds with *anti*-selectivity to generate an adduct that can be elaborated, as shown above, to the non-natural enantiomeric form of the protoilludane framework. The adducts in both enantiomeric series are readily converted through straightforward manipulations of the diol residue into the corresponding cyclopentannulated bicyclo[2.2.2]oct-5-en-2-ones that then participate in a photochemically promoted 1,3-acyl migration reaction (Givens rearrangement) to afford the protoilludane framework. In principle, the functionality embodied in both the initially produced Diels–Alder adducts and the derived photoproducts allows for their manipulation in ways relevant to the total synthesis of many other protoilludanes as well as a range of analogues. Work directed toward such ends continues in our laboratories.

EXPERIMENTAL SECTION

General Protocols. Unless otherwise specified, proton (^1H) and carbon (^{13}C) NMR spectra were recorded at room temperature in base-filtered CDCl_3 on a spectrometer operating at 400 MHz for proton and 100 MHz for carbon nuclei. The signal due to residual CHCl_3 appearing at δ_{H} 7.26 and the central resonance of the CDCl_3 “triplet” appearing at δ_{C} 77.0 were used to reference ^1H and ^{13}C NMR spectra, respectively. ^1H NMR data are recorded as follows: chemical shift (δ) [multiplicity, coupling constant(s) J (Hz), relative integral]

where multiplicity is defined as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, or combinations of the above. Infrared spectra (ν_{\max}) were recorded on a FTIR spectrometer. Samples were analyzed as thin films on KBr plates. Low-resolution ESI mass spectra were recorded on a single quadrupole liquid chromatograph-mass spectrometer, while high-resolution measurements were conducted on a time-of-flight instrument. Low- and high-resolution EI mass spectra were recorded on a magnetic-sector machine. Melting points were measured on an automated melting point system and are uncorrected. Analytical thin layer chromatography (TLC) was performed on aluminum-backed 0.2 mm thick silica gel 60 F₂₅₄ plates. Eluted plates were visualized using a 254 nm UV lamp and/or by treatment with a suitable dip followed by heating. These dips included (1) phosphomolybdic acid, ceric sulfate, sulfuric acid (conc), and water (37.5 g, 7.5 g, 37.5 g, and 720 mL, respectively); (2) potassium permanganate, potassium carbonate, 5% sodium hydroxide aqueous solution, and water (3 g, 20 g, 5 mL, and 300 mL, respectively); and (3) *p*-anisaldehyde or vanillin, sulfuric acid (conc), and ethanol (15 g, 2.5 mL, and 250 mL, respectively). Flash chromatographic separations were carried out following protocols defined by Still et al.¹⁷ with silica gel 60 (40–63 μm) as the stationary phase and using the AR- or HPLC-grade solvents as indicated. Starting materials, reagents, drying agents, and other inorganic salts were generally commercially available and were used as supplied. Tetrahydrofuran (THF), methanol, and dichloromethane were dried using a solvent purification system based on a technology originally described by Grubbs et al.¹⁸ Where necessary, reactions were performed under a nitrogen atmosphere.

Specific Chemical Transformations. **Compound 7.** A magnetically stirred solution of the β -epimeric form of alcohol **6**⁸ (240 mg, 0.86 mmol) in THF (8.5 mL) maintained at 0 °C was treated with sodium hydride (106 mg of a 60% dispersion in mineral oil, 4.42 mmol). The ensuing mixture was heated under reflux for 6 h before being cooled to room temperature and quickly treated with carbon disulfide (0.52 mL, 8.63 mmol). After 11 h, the reaction mixture was heated under reflux for 2 h before being cooled to room temperature and treated with iodomethane (0.59 mL, 9.48 mmol). After 2 h, the reaction mixture was heated under reflux for the third time for 6 h, then cooled to room temperature, and quenched with acetic acid (0.3 mL). The ensuing mixture was filtered through a pad of diatomaceous earth, and the filtrate was extracted with ethyl acetate (4 \times 10 mL). The combined organic phases were washed with NaHCO₃ (2 \times 10 mL of a saturated aqueous solution), then dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The resulting light yellow oil was subjected to flash chromatography (silica, 0:1 \rightarrow 1:9 *v/v* ethyl acetate/hexane gradient elution), and concentration of the appropriate fractions ($R_f = 0.4$) gave a white solid. Recrystallization (hexane) of this material afforded the β -epimeric form of xanthate **7** (220 mg, 69%) as an off-white, crystalline solid: mp = 195–196 °C, $[\alpha]_{\text{D}}^{25} = +36.8$ ($c = 1.0$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 5.96 (dd, $J = 6.0$ and 1.1 Hz, 1H), 5.92–5.87 (complex m, 2H), 4.24 (dd, $J = 7.2$ and 3.2 Hz, 1H), 3.82 (d, $J = 7.2$ Hz, 1H), 2.82–2.77 (complex m, 1H), 2.58 (s, 3H), 2.27 (m, 1H), 2.17 (dd, $J = 10.4$ and 6.0 Hz, 1H), 1.47 (ddd, $J = 11.9$, 7.2 , and 1.0 Hz, 1H), 1.39 (t, $J = 11.9$ Hz, 1H), 1.32 (s, 3H), 1.27 (s, 3H), 1.15 (s, 3H), 0.99 (s, 3H), 0.89 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 216.1, 137.3, 125.9, 109.1, 90.8, 83.9, 79.9, 50.1, 46.0, 42.2, 40.5, 40.0, 37.8, 25.5, 25.1, 22.5, 19.7, 19.0 (one signal obscured or overlapping). IR ν_{\max} : 2967, 2930, 2895, 2885, 1454, 1378, 1365, 1281, 1260, 1229, 1192, 1164, 1081, 1068, 1055, 1037, 1012, 890, 742 cm⁻¹. MS (EI, 70 eV): m/z 368 (M⁺, 58%), 353 [(M – CH₃)⁺, 48], 321 (18), 268 (25), 203 (45), 202 (58), 160 (100), 145 (63), 105 (67), 95 (93), 91 (78). HRMS (EI, 70 eV): m/z M⁺ calcd for C₁₉H₂₈O₃S₂ 368.1480, found 368.1480.

Subjection of the α -epimeric form of alcohol **6**⁸ to the above-mentioned reaction conditions afforded a dark residue on workup. Flash column chromatographic purification of this material (silica, 0:1 \rightarrow 1:9 *v/v* ethyl acetate/hexane gradient elution) and concentration of the appropriate fractions ($R_f = 0.5$) afforded a white solid. Recrystallization (diethyl ether) of this material afforded the α -epimeric form of xanthate **7** (87%) as a white, crystalline solid: mp = 140–141 °C, $[\alpha]_{\text{D}}^{25} = -10.8$ ($c = 1.0$, CHCl₃). ¹H NMR (400 MHz,

CDCl₃): δ 6.08 (ddd, $J = 8.3$, 6.3 , and 1.2 Hz, 1H), 5.86 (dq, $J = 8.3$ and 1.2 Hz, 1H), 5.65 (d, $J = 8.4$ Hz, 1H), 4.23 (ddd, $J = 7.3$, 3.3 , and 1.2 Hz, 1H), 3.82 (dd, $J = 7.2$ and 1.2 Hz, 1H), 2.72–2.69 (complex m, 1H), 2.56 (s, 3H), 2.31 (m, 1H), 2.02 (dd, $J = 10.8$ and 8.9 Hz, 1H), 1.57 (dd, $J = 12.8$ and 8.0 Hz, 1H), 1.31 (s, 3H), 1.30 (s, 3H), 1.20–1.25 (complex m, 1H), 1.17 (s, 3H), 0.97 (s, 3H), 0.96 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 215.9, 135.8, 131.0, 109.0, 90.8, 82.9, 79.5, 48.9, 43.6, 42.0, 40.6, 38.8, 37.6, 26.6, 25.5, 25.0, 22.6, 18.9, 18.8. IR ν_{\max} : 2962, 2935, 2888, 1463, 1375, 1256, 1207, 1166, 1057, 966, 886, 735, 719 cm⁻¹. MS (EI, 70 eV): m/z 353 [(M – CH₃)⁺, 25%], 202 (100), 187 (96), 160 (80), 145 (78), 105 (45), 95 (70), 91 (65). HRMS (EI, 70 eV): m/z (M – CH₃)⁺ calcd for C₁₈H₂₅O₃S₂ 353.1245, found 353.1248.

Compound 8. A magnetically stirred solution of the β -epimeric form of xanthate **7** (6.20 g, 16.84 mmol) and AIBN (39 mg, 0.24 mmol) in toluene (230 mL) was treated, in one portion, with tri-*n*-butyltin hydride (13.8 mL, 51.36 mmol), and the resulting solution was stirred at 100 °C for 16 h. The cooled reaction mixture was treated with additional tri-*n*-butyltin hydride (9.2 mL, 34.24 mmol) and AIBN (58 mg, 0.35 mmol), and the resulting mixture was heated under reflux for 1 h. The cooled reaction mixture was concentrated under reduced pressure, and the residue was subjected to flash chromatography (silica, 0:1 \rightarrow 1:49 *v/v* ethyl acetate/hexane gradient elution). Concentration of the relevant fractions ($R_f = 0.5$ in 1:9 *v/v* ethyl acetate/hexane) afforded the title acetone **8** (3.87 g, 87%) as a clear, colorless oil: $[\alpha]_{\text{D}}^{25} = +1.8$ ($c = 1.0$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 5.99 (dd, $J = 8.2$ and 6.4 Hz, 1H), 5.73 (dd, $J = 8.2$ and 1.2 Hz, 1H), 4.21 (dd, $J = 7.2$ and 3.2 Hz, 1H), 3.82 (dd, $J = 7.2$ and 1.2 Hz, 1H), 2.71 (dt, $J = 6.2$ and 2.9 Hz, 1H), 2.17 (m, 1H), 1.82 (m, 1H), 1.45–1.23 (complex m, 2H), 1.32 (s, 3H), 1.28 (s, 3H), 1.16 (s, 3H), 1.05–0.90 (complex m, 2H), 0.96 (s, 3H), 0.88 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 135.6, 130.3, 108.6, 83.7, 79.9, 45.4, 44.9, 43.2, 41.4, 40.5, 39.6, 38.9, 28.4, 27.7, 25.6, 25.0, 19.9. IR ν_{\max} : 2953, 2931, 2872, 2895, 1459, 1377, 1274, 1255, 1207, 1166, 1078, 1066, 1029, 895, 879, 850, 826, 733, 707 cm⁻¹. MS (EI, 70 eV): m/z 247 [(M – CH₃)⁺, 27%], 204 (80), 162 (100). HRMS (EI, 70 eV): m/z (M – CH₃)⁺ calcd for C₁₆H₂₃O₂ 247.1698, found 247.1704.

Treatment of the α -epimeric form of xanthate **7** using the same procedure as described immediately above afforded, after workup and flash chromatography, compound **8** (89%, 23 mmol scale) as a clear, colorless oil. This material was identical in all respects with that obtained by reduction of the major epimeric form of compound **7**.

Compound 9. A magnetically stirred solution of acetone **8** (2.09 g, 7.98 mmol) in methanol/water (120 mL of a 5:1 *v/v* mixture) was treated with DOWEX-50 resin (4.07 g of the acidified form). The ensuing mixture was heated at 70 °C for 72 h and then cooled, and the resin was removed by filtration and washed with methanol (3 \times 50 mL). The combined filtrates were concentrated under reduced pressure, and the residue was diluted with brine (10 mL) and then extracted with ethyl acetate (3 \times 50 mL). The combined organic fractions were dried (Na₂SO₄), filtered, and concentrated under reduced pressure, and the residue obtained was subjected to column chromatography (silica, 1:20 \rightarrow 1:1 *v/v* ethyl acetate/hexane gradient elution) which afforded fractions A and B.

Concentration of fraction A ($R_f = 0.8$ in 3:7 *v/v* ethyl acetate/hexane) afforded the starting acetone **8** (550 mg, 26% recovery) that was identical in all respects to the authentic material.

Concentration of fraction B ($R_f = 0.8$ in 3:7 *v/v* ethyl acetate/hexane) afforded a solid that, after recrystallization (hexane), afforded diol **9** (940 mg, 72% or 97% brsm) as a white, crystalline solid: mp = 84–85 °C, $[\alpha]_{\text{D}}^{25} = -11.0$ ($c = 1.0$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 6.16 (dd, $J = 8.2$ and 6.4 Hz, 1H), 5.86 (dd, $J = 8.2$ and 1.4 Hz, 1H), 3.89 (dd, $J = 7.5$ and 2.8 Hz, 1H), 3.46 (dd, $J = 7.5$ and 1.2 Hz, 1H), 2.69 (m, 1H), 2.25–2.18 (complex m, 3H), 1.89 (td, $J = 10.3$ and 7.7 Hz, 1H), 1.43 (m, 2H), 1.18 (s, 3H), 1.04–0.87 (complex m, 2H), 0.95 (s, 3H), 0.87 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 136.8, 131.9, 75.2, 71.8, 46.3, 45.0, 43.9, 43.0, 41.8, 41.0, 38.9, 28.4, 27.7, 19.6. IR ν_{\max} : 3369, 2951, 2928, 2869, 1459, 1365, 1118, 1077, 1053, 1031, 1014, 807, 731, 707 cm⁻¹. MS (EI, 70 eV): m/z 222 (M⁺,

< 1%), 162 (95), 147 (43), 106 (45), 86 (72), 84 (100). HRMS (EI, 70 eV): m/z M^{+} calcd for $C_{14}H_{22}O_2$ 222.1620, found 222.1626.

Compound 10. A magnetically stirred solution of diol **9** (1.09 g, 4.91 mmol) and *p*-TsOH·H₂O (2.05 g, 10.8 mmol) in dichloromethane (90 mL) was cooled to 0 °C, and 4-acetamido-TEMPO (2.30 g, 10.8 mmol) was added in portions over 2 h. The ensuing mixture was stirred for 2 h and then quenched with NaHCO₃ (100 mL of a saturated aqueous solution). The separated aqueous phase was extracted with dichloromethane (3 × 50 mL), and the combined organic fractions were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The resulting orange oil was subjected to flash chromatography (silica, 1:9 *v/v* ethyl acetate/hexane elution) which afforded, after concentration of the appropriate fractions ($R_f = 0.6$ in 3:7 *v/v* ethyl acetate/hexane), a white solid. Recrystallization (ethyl acetate) of this material gave acyloin **10** (972 mg, 90%) as a white, crystalline solid: mp = 86–87 °C, $[\alpha]_D^{25} = +202.2$ ($c = 1.0$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 6.09 (t, $J = 7.6$ Hz, 1H), 6.02 (d, $J = 7.6$ Hz, 1H), 3.38 (s, 1H), 3.11 (dd, $J = 6.5$ and 2.5 Hz, 1H), 2.63 (m, 1H), 2.27 (td, $J = 10.4$ and 7.4 Hz, 1H), 1.55 (m, 2H), 1.25 (s, 3H), 1.08 (m, 2H), 1.00 (s, 3H), 0.93 (s, 3H) (signal due to hydroxyl group proton not observed). ¹³C NMR (100 MHz, CDCl₃): δ 211.9, 140.3, 126.5, 75.0, 51.1, 47.7, 44.9, 44.7, 43.6, 39.1, 38.9, 28.3, 27.6, 18.3. IR ν_{max} : 3418, 2947, 2931, 2898, 2853, 1727, 1457, 1402, 1381, 1365, 1270, 1210, 1136, 1079, 1035, 993, 789, 764, 713, 655 cm⁻¹. MS (EI, 70 eV): m/z 220 (M^{+} , 100%), 205 (33), 192 (25), 163 (80), 161 (62), 147 (48), 107 (55), 105 (60), 91 (70). HRMS (EI, 70 eV): M^{+} m/z calcd for $C_{14}H_{20}O_2$ 220.1463, found 220.1465.

Compound 11. A magnetically stirred solution of acyloin **10** (938 mg, 4.26 mmol) in dichloromethane (70 mL) maintained at 0 °C was successively treated, in portions, with triethylamine (13.3 mL, 96.0 mmol), benzoyl chloride (1.2 mL, 10.2 mmol), and DMAP (1.72 g, 14.1 mmol). The ensuing mixture was stirred at 18 °C for 16 h and then quenched with HCl (200 mL of a 1 M aqueous solution). The separated aqueous phase was extracted with dichloromethane (3 × 100 mL), and the combined organic fractions were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The yellow oil thus obtained was subjected to flash chromatography (silica, 1:9 *v/v* ethyl acetate/hexane elution) to give, after concentration of the appropriate fractions ($R_f = 0.8$ in 1:4 *v/v* ethyl acetate/hexane), a white solid. Recrystallization (dichloromethane) of this material afforded compound **11** (1.24 g, 90%) as a white, crystalline solid: mp = 82–83 °C, $[\alpha]_D^{25} = +135.2$ ($c = 1.0$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.03–7.99 (complex m, 2H), 7.58–7.53 (complex m, 1H), 7.44–7.40 (complex m, 2H), 6.21 (t, $J = 7.2$ Hz, 1H), 6.12 (d, $J = 7.2$ Hz, 1H), 5.13 (s, 1H), 3.18 (dd, $J = 6.6$ and 2.6 Hz, 1H), 2.79–2.70 (complex m, 1H), 2.47 (m, 1H), 1.63–1.54 (complex m, 3H), 1.18–1.05 (complex m, 1H), 1.14 (s, 3H), 1.02 (s, 3H), 0.96 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 205.9, 166.2, 139.4, 133.2, 129.9, 129.5, 128.3, 127.0, 74.5, 51.8, 47.3, 44.7, 43.9, 43.8, 39.3, 39.2, 28.2, 27.6, 18.4. IR ν_{max} : 2953, 2861, 1742, 1724, 1269, 1111, 1070, 1028, 708 cm⁻¹. MS (EI, 70 eV): m/z 324 (M^{+} , 2%), 202 (35%), 162 (40), 106 (35), 105 (100). HRMS (EI, 70 eV): m/z M^{+} calcd for $C_{21}H_{24}O_3$ 324.1725, found 324.1732.

Compound 12. A magnetically stirred solution of benzoate **11** (1.20 g, 3.70 mmol) in THF/methanol (55 mL of a 2:1 *v/v* mixture) was cooled to –78 °C, and then SmI₂ (~150 mL of a 0.1 M solution in THF) was added dropwise until complete consumption of starting material was observed (determined by TLC). The ensuing mixture was stirred at –78 °C for 0.25 h and then poured directly into K₂CO₃ (100 mL of a saturated solution), and the mixture formed was extracted with diethyl ether (3 × 100 mL). The combined organic phases were washed with brine (1 × 20 mL) before being dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The light yellow oil obtained was subjected to flash chromatography (silica, 3:97 *v/v* ethyl acetate/hexane elution) to afford, after concentration of the relevant fractions ($R_f = 0.4$ in 1:9 *v/v* ethyl acetate/hexane), compound **12** (604 mg, 80%) as a clear, colorless oil: $[\alpha]_D^{25} = +196.4$ ($c = 1.0$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 6.13–6.07 (complex m, 2H), 3.02 (dt, $J = 5.2$ and 2.4 Hz, 1H), 2.63 (m, 1H), 2.25 (m, 1H), 1.88 (ABq, $J = 18.1$ Hz, 2H), 1.50–1.43 (complex m, 2H), 1.16 (s,

3H), 1.12–1.05 (complex m, 2H), 0.98 (s, 3H), 0.91 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 213.5, 141.4, 127.7, 53.4, 49.7, 46.9, 44.5, 44.4, 42.0, 40.4, 39.4, 28.4, 27.7, 22.2. IR ν_{max} : 3037, 2953, 2869, 1729, 1458, 1405, 1382, 1366, 1264, 1202, 1091, 912, 799, 715 cm⁻¹. MS (EI, 70 eV): m/z 204 (M^{+} , 20%), 163 (25), 162 (100), 147 (45), 106 (45), 91 (40). HRMS (EI, 70 eV): m/z M^{+} calcd for $C_{14}H_{20}O$ 204.1514, found 204.1518.

Compound 13. A magnetically stirred solution of ketone **12** (100 mg, 0.49 mmol) in deoxygenated and dry dichloromethane (15 mL) was irradiated for 14 h at 5 °C using a standard (125 W) high-pressure mercury lamp (CAUTION: avoid eye contact with illuminated lamp) equipped with a water-jacketed cooling system to maintain the required reaction temperature. The reaction mixture was then concentrated under reduced pressure, and the residue obtained was subjected to flash column chromatography (silica, 1:49 *v/v* ether/hexane elution) which afforded fractions A and B.

Concentration of fraction A ($R_f = 0.5$ in 1:9 *v/v* ethyl acetate/hexane) afforded cyclobutanone **13** (28 mg, 28% or 54% brsm) as a clear, colorless oil: $[\alpha]_D^{25} = -607.0$ ($c = 1.1$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 5.64 (d, $J = 10.0$ Hz, 1H), 5.50 (ddd, $J = 5.2$, and 2.8 Hz, 1H), 3.17 (m, 1H), 3.03 (dd, $J = 16.4$ and 2.4 Hz, 1H), 2.67–2.60 (complex m, 1H), 2.52 (dd, $J = 16.4$ and 5.6 Hz, 1H), 2.33 (dt, $J = 14.0$ and 7.2 Hz, 1H), 1.88 (dd, $J = 14.0$ and 8.4 Hz, 1H), 1.55–1.43 (complex m, 2H), 1.23 (s, 3H), 1.13 (t, $J = 12.5$ Hz, 1H), 1.03 (s, 3H), 1.02 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 206.4, 133.8, 118.6, 62.5, 55.5, 47.5, 43.3, 43.0, 38.6, 38.0, 32.1, 32.0, 29.9, 26.4. IR ν_{max} : 3018, 2951, 2927, 2866, 1781, 698 cm⁻¹. MS (EI, 70 eV): m/z 204 (M^{+} , 1%), 162 (100), 147 (72), 106 (75), 105 (45), 91 (68). HRMS (EI, 70 eV): m/z M^{+} calcd for $C_{14}H_{20}O$ 204.1514, found 204.1514.

Concentration of fraction B ($R_f = 0.4$ in 1:9 *v/v* ethyl acetate/hexane) afforded the starting material **12** (49 mg, 49% recovery) as a clear, colorless oil that was identical in all respects to the authentic material.

Compounds 14 and 15. A magnetically stirred solution of cyclobutanone **13** (57 mg, 0.28 mmol) in acetone (1.0 mL) maintained under nitrogen was cooled to ca. 0 °C and then treated dropwise with DMDO¹⁵ (~8.3 mL of a 0.034 M solution in acetone, 0.28 mmol). The ensuing mixture was stirred at ca. 0 °C for 4 h and then concentrated under reduced pressure. The resulting clear, colorless oil was subjected to flash chromatography (silica, 1:19 *v/v* ethyl acetate/hexane elution) which afforded fractions A and B.

Concentration of fraction A [$R_f = 0.5(1)$ in 1:4 *v/v* ethyl acetate/hexane] afforded a white solid. Recrystallization (pentane) of this material afforded epoxide **14** (11 mg, 18%) as a white, crystalline solid: mp = 44–46 °C, $[\alpha]_D^{25} = -214$ ($c = 2.7$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 3.16 (m, 1H), 3.11–3.02 (complex m, 3H), 2.61–2.50 (complex m, 2H), 2.23 (dt, $J = 13.9$ and 7.2 Hz, 1H), 1.88 (dd, $J = 13.6$ and 9.2 Hz, 1H), 1.71 (dd, $J = 13.6$ and 3.0 Hz, 1H), 1.50 (dd, $J = 13.3$ and 11.8 Hz, 1H), 1.32 (dd, $J = 11.8$ and 6.9 Hz, 1H), 1.16 (s, 3H), 1.09 (s, 3H), 0.99 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 206.8, 61.2, 57.2, 56.9, 52.0, 45.1, 44.6, 44.5, 37.2, 34.7, 31.4, 30.2, 29.7, 27.0. IR ν_{max} : 2950, 2630, 2865, 1779 cm⁻¹. MS (ESI, +ve): m/z 285 [(M + Na + MeCN)⁺, 100%], 243 [(M + Na)⁺, 85], 221 [(M + H)⁺, 47]. HRMS (ESI, +ve): m/z (M + H)⁺ calcd for $C_{14}H_{21}O_2$ 221.1542, found 221.1535.

Concentration of fraction B [$R_f = 0.4(6)$ in 1:4 *v/v* ethyl acetate/hexane] afforded a white solid. Recrystallization (pentane) of this material afforded epoxide **15** (35 mg, 57% yield) as a white, crystalline solid: mp = 40–41 °C, $[\alpha]_D^{25} = -135$ ($c = 4.8$, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 3.28 (dd, $J = 5.8$ and 3.6 Hz, 1H), 2.92–2.84 (complex m, 2H), 2.88 (dd, $J = 5.8$ and 2.1 Hz, 1H), 2.38 (m, 1H), 2.27 (dd, $J = 16.6$ and 6.2 Hz, 1H), 2.13 (m, 1H), 1.85 (dd, $J = 13.7$ and 8.5 Hz, 1H), 1.53 (dd, $J = 13.7$ and 2.6 Hz, 1H), 1.47 (dd, $J = 12.7$ and 6.6 Hz, 1H), 1.09 (s, 3H), 0.97 (s, 3H), 0.97 (t, $J = 12.7$ Hz, 1H), 0.96 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 204.7, 58.7, 57.9, 55.5, 50.5, 46.3, 44.3, 41.5, 36.5, 36.4, 31.0, 30.7, 28.5, 27.3. IR ν_{max} : 2950, 2929, 2867, 1783 cm⁻¹. MS (ESI, +ve): m/z 284 [(M + Na + MeCN)⁺, 100%], 243 [(M + Na)⁺, 25], 221 [(M + H)⁺, 5]. HRMS

(ESI, +ve): m/z ($M + Na$)⁺ calcd for $C_{14}H_{20}NaO_2$ 243.1361, found 243.1365.

Compound 16. A magnetically stirred solution of epoxide **15** (1.10 g, 5.4 mmol) in THF (54 mL) maintained under nitrogen was cooled to -78 °C, and then LiHMDS (6.5 mL of a 1.0 M solution in THF, 6.5 mmol) was added dropwise. The ensuing mixture was warmed to 18 °C over 16 h before being quenched with NH_4Cl (50 mL of a saturated aqueous solution) and extracted with diethyl ether (3×50 mL). The combined organic phases were washed with brine (1×50 mL), then dried ($MgSO_4$), filtered, and concentrated under reduced pressure. The residue obtained was subjected to flash chromatography (silica, 1:19 \rightarrow 1:5 v/v ethyl acetate/hexane gradient elution) and afforded fractions A and B.

Concentration of fraction A ($R_f = 0.6$ in 3:7 v/v ethyl acetate/hexane) afforded the starting epoxide **15** (431 mg, 39% recovery) which proved identical in all respects to the authentic material.

Concentration of fraction B ($R_f = 0.3$ in 3:7 v/v ethyl acetate/hexane) afforded a white solid. Recrystallization (pentane) of this material gave the title compound **16** (616 mg, 56%) as a white, crystalline solid: mp = $80-81$ °C, $[\alpha]_D^{25} = +368$ ($c = 1.1$, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ 6.39 (d, $J = 2.2$ Hz, 1H), 4.13 (dd, $J = 8.0$ and 2.2 Hz, 1H), 3.57 (broad s, 1H), 2.70 (ABq, $J = 16.9$ Hz, 2H), 2.40–2.27 (complex m, 2H), 1.81 (dd, $J = 12.5$ and 5.5 Hz, 1H), 1.51–1.44 (complex m, 1H), 1.42–1.34 (complex m, 1H), 1.15 (m, 1H), 1.15 (s, 3H), 1.14 (s, 3H), 1.00 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 197.0, 155.8, 132.8, 72.7, 60.9, 52.1, 46.5, 46.1, 41.0, 40.2, 36.9, 29.4, 26.8, 20.2. IR ν_{max} : 3428, 2951, 2866, 1748, 1734, 1657, 1464, 1199, 1142, 1094, 854, 844 cm^{-1} . MS (ESI, +ve): m/z 462 [($2M + Na$)⁺, 55%], 413 (100), 275 [($M + Na + CH_3OH$)⁺, 51], 243 [($M + Na$)⁺, 49]. HRMS (ESI, +ve): m/z ($M + Na$)⁺ calcd for $C_{14}H_{20}NaO_2$ 243.1361, found 243.1362.

Compounds ent-1 and 18. A magnetically stirred solution of CuI (1.66 g, 8.73 mmol) in THF (8.7 mL) maintained at 0 °C was treated with MeLi (11.0 mL of a 1.6 M solution in diethyl ether, 17.5 mmol), and the resulting mixture was stirred at 0 °C for 0.75 h. A solution of compound **16** (640 mg, 2.91 mmol) in THF (29 mL) was then added dropwise to the colorless reaction mixture and stirring continued at 0 °C for 1 h. The ensuing mixture was quenched with NH_4Cl (100 mL of a saturated aqueous solution) and extracted with diethyl ether (3×100 mL). The combined organic phases were dried ($MgSO_4$), filtered, and concentrated under reduced pressure. The resulting light yellow oil was subjected to flash chromatography (silica, 3:17 v/v ethyl acetate/hexane elution) to afford fractions A and B.

Concentration of fraction A ($R_f = 0.4(2)$ in 3:7 v/v ethyl acetate/hexane) afforded a white solid, recrystallization (chloroform/hexanes) of which gave compound **18** (198 mg, 31%) as a colorless, crystalline solid: mp = $213-215$ °C, $[\alpha]_D^{25} = +74$ ($c = 1.0$, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ 3.85–3.75 (complex m, 2H), 3.40 (dt, $J = 8.6$ and 2.0 Hz, 1H), 3.35 (dd, $J = 11.2$ and 9.3 Hz, 1H), 3.07 (d, $J = 16.2$ Hz, 1H), 2.76 (dd, $J = 16.2$ and 2.2 Hz, 1H), 2.60–2.50 (complex m, 2H), 2.32 (dt, $J = 12.3$ and 7.0 Hz, 1H), 2.21–2.03 (complex m, 3H), 1.88–1.72 (complex m, 2H), 1.67–1.54 (complex m, 3H), 1.51–1.39 (complex m, 2H), 1.37 (s, 3H), 1.32 (s, 3H), 1.27–1.19 (complex m, 2H), 1.13 (s, 3H), 1.10 (s, 3H), 1.02 (s, 3H), 0.96 (s, 3H) (signal due to hydroxyl group proton not observed). ^{13}C NMR (100 MHz, $CDCl_3$): δ 208.3, 205.9, 83.9, 82.6, 73.5, 73.1, 65.8, 59.0, 57.8, 47.2, 46.3, 44.6, 44.2, 43.6, 43.4, 42.8(0), 42.7(8), 41.0, 39.0, 37.2, 35.3, 32.3, 32.0, 31.7, 29.5, 28.5, 26.8, 23.1. IR ν_{max} : 3414, 2948, 2902, 2863, 1773, 1453, 1386, 1363, 1200, 1076, 1049, 1028 cm^{-1} . MS (ESI): m/z 463 [($M + Na$)⁺, 100%]. HRMS (ESI, +ve): m/z ($M + Na$)⁺ calcd for $C_{28}H_{40}NaO_4$ 463.2824, found 463.2822.

Concentration of fraction B ($R_f = 0.4(0)$ in 3:7 v/v ethyl acetate/hexane) afforded *ent*-8-deoxydihydrotsugicolone (*ent*-1) (384 mg, 56%) as a clear, colorless oil: $[\alpha]_D^{25} = -24$ ($c = 2.4$, methanol), $[\alpha]_D^{25} = -3.1$ ($c = 1.0$, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ 3.06 (t, $J = 10.3$ Hz, 1H), 2.98 (dd, $J = 16.0$ and 2.2 Hz, 1H), 2.55 (dd, $J = 16.0$ and 4.8 Hz, 1H), 2.48 (ddd, $J = 9.6$, 4.9 , and 2.2 Hz, 1H), 2.34 (m, 1H), 2.04–1.91 (complex m, 1H), 1.66 (dd, $J = 12.9$ and 7.1 Hz, 1H), 1.63–1.51 (complex m, 3H), 1.39 (dd, $J = 12.9$ and 10.8 Hz, 1H), 1.23 (s, 3H), 1.13 (s, 3H), 1.06 (d, $J = 6.4$ Hz, 3H), 0.97 (s, 3H) (signal

due to hydroxyl group proton not observed). 1H NMR (400 MHz, CD_3OD): δ see Table 1. ^{13}C NMR (100 MHz, $CDCl_3$): δ 208.5, 74.6, 70.4, 57.6, 46.8, 44.9, 44.5, 43.1, 37.5, 36.6, 31.1, 30.4, 29.9, 26.9, 17.8. ^{13}C NMR (100 MHz, CD_3OD): δ see Table 1. IR ν_{max} : 3414, 2951, 2927, 2868, 1772, 1463, 1045 cm^{-1} . MS (ESI, +ve): m/z 259 [($M + Na$)⁺, 100%]. HRMS (ESI, +ve): m/z ($M + Na$)⁺ calcd for $C_{15}H_{24}NaO_2$ 259.1674, found 259.1674.

Compounds ent-2 and 17. A magnetically stirred solution of compound *ent*-1 (48 mg, 0.20 mmol) in THF (20 mL) maintained under nitrogen was cooled to 0 °C and then treated dropwise with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al, 130 μ L of a 60 wt % solution in toluene, 0.40 mmol). The ensuing mixture was warmed to 18 °C over 1 h before being heated under reflux for 1 h. The cooled reaction mixture was quenched with HCl (10 of a 1 M aqueous solution) and extracted with diethyl ether (3×50 mL), and the combined organic phases washed with brine (1×50 mL), then dried ($MgSO_4$), filtered, and concentrated under reduced pressure. The residue obtained was subjected to flash chromatography (silica, 9:1 v/v dichloromethane/methanol elution), and fractions A and B were collected.

Concentration of fraction A ($R_f = 0.3(6)$ in 9:1 v/v dichloromethane/methanol) afforded a white solid, recrystallization (methanol) of which gave compound *ent*-2 (21 mg, 41%) as a colorless, crystalline solid: mp = $135-136$ °C, $[\alpha]_D^{25} = -24.0$ ($c = 1.0$, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ see Table 2. ^{13}C NMR (400 MHz, CD_3OD): δ 3.90 (q, $J = 7.1$ Hz, 1H), 3.06 (dd, $J = 11.0$ and 9.6 Hz, 1H), 2.40 (m, 1H), 2.18–2.04 (complex m, 2H), 1.74 (ddd, $J = 12.2$, 6.9 , and 1.5 Hz, 1H), 1.66 (t, $J = 7.3$ Hz, 1H), 1.53 (dd, $J = 13.3$ and 8.9 Hz, 1H), 1.50–1.43 (complex m, 3H), 1.23 (t, $J = 12.0$ Hz, 1H), 1.08 (s, 3H), 1.07 (s, 3H), 1.06 (d, $J = 6.0$ Hz, 3H), 0.99 (s, 3H) (signal due to hydroxyl group proton not observed). ^{13}C NMR (100 MHz, $CDCl_3$): δ see Table 2. ^{13}C NMR (100 MHz, CD_3OD): δ 77.2, 72.1, 62.2, 49.0, 47.9, 45.9, 44.4, 43.1, 42.4, 39.4, 32.2, 30.2, 29.3, 18.6 (one signal was obscured or overlapping). IR ν_{max} : 3324, 2951, 2926, 2867, 1463, 1376, 1363, 1316, 1262, 1224, 1133, 1102, 1080, 1054, 1033, 1015, 999 cm^{-1} . MS (ESI, +ve): m/z 261 [($M + Na$)⁺, 100%]. HRMS (ESI, +ve): ($M + Na$)⁺ calcd for $C_{15}H_{26}NaO_2$ 261.1831, found 261.1830.

Concentration of fraction B ($R_f = 0.3(3)$ in 9:1 v/v dichloromethane/methanol) afforded a white solid that, upon recrystallization (ethyl acetate), afforded the title compound **17** (25 mg, 53%) as a white, crystalline solid: mp = $153-155$ °C, $[\alpha]_D^{25} = +45$ ($c = 1.0$, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ 4.44 (q, $J = 7.2$ Hz, 1H), 3.08 (t, $J = 10.4$ Hz, 1H), 2.05 (dt, $J = 13.4$ and 6.7 Hz, 1H), 2.00 (dd, $J = 10.8$ and 7.2 Hz, 1H), 1.98 (d, $J = 8.5$ Hz, 1H), 1.95–1.67 (complex m, 6H), 1.56 (dd, $J = 13.9$ and 7.6 Hz, 1H), 1.39 (dd, $J = 12.4$ and 6.6 Hz, 1H), 1.24 (t, $J = 12.9$ Hz, 1H), 1.09 (s, 3H), 1.04 (d, $J = 6.5$ Hz, 3H), 1.02 (s, 3H), 0.97 (s, 3H). 1H NMR (400 MHz, CD_3OD): δ 4.37 (m, 1H), 2.94–3.03 (complex m, 1H), 2.05 (dt, $J = 6.6$ and 6.4 Hz, 1H), 2.00 (dd, $J = 10.3$ and 8.5 Hz, 1H), 1.94–1.85 (complex m, 3H), 1.83–1.73 (complex m, 2H), 1.52 (dd, $J = 13.9$ and 7.6 Hz, 1H), 1.39 (dd, $J = 12.4$ and 6.7 Hz, 1H), 1.28 (t, $J = 12.9$ Hz, 1H), 1.10 (s, 3H), 1.03 (s, 3H), 0.99 (d, $J = 5.3$ Hz, 3H), 0.98 (s, 3H) (signal due to hydroxyl group proton not observed). ^{13}C NMR (100 MHz, $CDCl_3$): δ 74.7, 64.8, 52.5, 48.4, 46.3, 43.6, 43.1, 42.7, 36.4, 34.6, 32.4, 31.8, 30.2, 26.8, 19.0. ^{13}C NMR (100 MHz, CD_3OD): δ 75.1, 65.0, 54.3, 50.1, 47.5, 44.6, 44.3, 42.8, 37.2, 35.7, 32.9, 32.5, 31.3, 27.3, 19.5. IR ν_{max} : 3324, 2952, 2926, 2866, 1454, 1364, 1196, 1088, 1031 cm^{-1} . MS (ESI, +ve): m/z 261 [($M + Na$)⁺, 100%], 177 (10). HRMS (ESI, +ve): ($M + Na$)⁺ calcd for $C_{15}H_{26}NaO_2$ 261.1831, found 261.1831.

Compound 19. A solution of compound *ent*-1 in dichloromethane (24 mg in 10 mL) was left to evaporate over 4 days at 18 °C while exposed to air. The residue obtained was subjected to flash chromatography (silica, 3:17 v/v ethyl acetate/hexane elution) and afforded a white solid after concentration of the appropriate fractions ($R_f = 0.5$ in 3:7 v/v ethyl acetate/hexane). Recrystallization (dichloromethane) of this material gave lactone **19** (14 mg, 53%) as a white, crystalline solid: mp = $126-127$ °C, $[\alpha]_D^{25} = -63.0$ ($c = 0.4$, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ 3.86 (d, $J = 9.9$ Hz, 1H),

3.13 (t, $J = 10.7$ Hz, 1H), 2.68 (d, $J = 16.9$ Hz, 1H), 2.32 (m, 1H), 2.11 (d, $J = 16.9$ Hz, 1H), 1.98–1.90 (complex m, 1H), 1.80 (dd, $J = 13.9$ and 1.7 Hz, 1H), 1.62 (dd, $J = 13.9$ and 7.0 Hz, 1H), 1.55 (dd, $J = 12.6$ and 7.0 Hz, 1H), 1.43 (m, 1H), 1.30 (m, 1H), 1.19 (d, $J = 6.4$ Hz, 3H), 1.13 (s, 6H), 1.03 (s, 3H) (signal due to hydroxyl group proton not observed). ^{13}C NMR (100 MHz, CDCl_3): δ 176.2, 89.5, 72.9, 45.6, 45.1, 43.4, 43.0, 42.9, 41.7, 40.4, 36.4, 32.5, 32.0, 25.3, 15.1. IR ν_{max} : 3427, 2950, 2929, 2869, 1763, 1455, 1159, 1050, 1001, 980 cm^{-1} . MS (ESI, +ve): m/z 527 [(2M + Na) $^+$, 53%], 275 [(M + Na) $^+$, 100]. HRMS (ESI, +ve): m/z (M + Na) $^+$ calcd for $\text{C}_{15}\text{H}_{24}\text{NaO}_3$, 275.1623, found 275.1620.

Crystallographic Studies. *Crystallographic Data for Compound ent-2.* $\text{C}_{15}\text{H}_{26}\text{O}_2$, $M = 238.37$, $T = 150$ K, hexagonal, space group $P6_3$, $Z = 6$, $a = 21.353(3)$ Å, $c = 5.8048(10)$ Å, $V = 2292.1(6)$ Å 3 , $D_x = 1.036$ g cm^{-3} , 1483 unique data ($2\theta_{\text{max}} = 143.4^\circ$), $R = 0.081$ [for 1113 reflections with $I > 2.0\sigma(I)$], $R_w = 0.190$ (all data), $S = 1.02$.

Crystallographic Data for Compound 7 (β -epimer). $\text{C}_{19}\text{H}_{28}\text{O}_3\text{S}_2$, $M = 368.56$, $T = 150$ K, orthorhombic, space group $P2_12_12_1$, $Z = 4$, $a = 6.2794(1)$ Å, $b = 13.2695(1)$ Å, $c = 23.5284(2)$ Å, $V = 1960.49(4)$ Å 3 , $D_x = 1.249$ g cm^{-3} , 3887 unique data ($2\theta_{\text{max}} = 144.6^\circ$), $R = 0.022$ [for 3815 reflections with $I > 2.0\sigma(I)$], $R_w = 0.058$ (all data), $S = 1.01$.

Crystallographic Data for Compound 14. $\text{C}_{14}\text{H}_{20}\text{O}_2$, $M = 220.31$, $T = 150$ K, orthorhombic, space group $P2_12_12_1$, $Z = 4$, $a = 5.8991(1)$ Å, $b = 12.6249(1)$ Å, $c = 16.8455(2)$ Å, $V = 1254.58(3)$ Å 3 , $D_x = 1.166$ g cm^{-3} , 2476 unique data ($2\theta_{\text{max}} = 144.6^\circ$), $R = 0.029$ [for 2476 reflections with $I > 2.0\sigma(I)$], $R_w = 0.075$ (all data), $S = 1.00$.

Crystallographic Data for Compound 15. $\text{C}_{14}\text{H}_{20}\text{O}_2$, $M = 220.31$, $T = 150$ K, orthorhombic, space group $P2_12_12_1$, $Z = 4$, $a = 7.0022(1)$ Å, $b = 12.5744(1)$ Å, $c = 14.0683(2)$ Å, $V = 1238.69(3)$ Å 3 , $D_x = 1.181$ g cm^{-3} , 2452 unique data ($2\theta_{\text{max}} = 144.4^\circ$), $R = 0.025$ [for 2398 reflections with $I > 2.0\sigma(I)$], $R_w = 0.066$ (all data), $S = 1.00$.

Crystallographic Data for Compound 16. $\text{C}_{14}\text{H}_{20}\text{O}_2$, $M = 220.31$, $T = 150$ K, orthorhombic, space group $P2_12_12_1$, $Z = 4$, $a = 8.3922(1)$ Å, $b = 8.6217(1)$ Å, $c = 17.1215(1)$ Å, $V = 1238.83(2)$ Å 3 , $D_x = 1.181$ g cm^{-3} , 2457 unique data ($2\theta_{\text{max}} = 144.8^\circ$), $R = 0.026$ [for 2433 reflections with $I > 2.0\sigma(I)$], $R_w = 0.068$ (all data), $S = 1.01$.

Crystallographic Data for Compound 17. $\text{C}_{15}\text{H}_{26}\text{O}_2$, $M = 238.37$, $T = 150$ K, monoclinic, space group $C2$, $Z = 12$, $a = 33.1997(4)$ Å, $b = 9.6115(1)$ Å, $c = 13.8952(2)$ Å, $\beta = 99.7857(12)^\circ$, $V = 4369.43(10)$ Å 3 , $D_x = 1.087$ g cm^{-3} , 7638 unique data ($2\theta_{\text{max}} = 144.8^\circ$), $R = 0.035$ [for 7219 reflections with $I > 2.0\sigma(I)$], $R_w = 0.087$ (all data), $S = 1.00$.

Crystallographic Data for Compound 18. $\text{C}_{28}\text{H}_{40}\text{O}_4$, $M = 440.62$, $T = 150$ K, monoclinic, space group $P2_1$, $Z = 4$, $a = 6.5903(1)$ Å, $b = 27.7886(4)$ Å, $c = 13.8017(2)$ Å, $\beta = 101.7474(15)^\circ$, $V = 2474.64(6)$ Å 3 , $D_x = 1.183$ g cm^{-3} , 9541 unique data ($2\theta_{\text{max}} = 144.6^\circ$), $R = 0.038$ [for 8925 reflections with $I > 2.0\sigma(I)$], $R_w = 0.087$ (all data), $S = 1.00$.

Crystallographic Data for Compound 19. $\text{C}_{15}\text{H}_{24}\text{O}_3$, $M = 252.35$, $T = 150$ K, monoclinic, space group $P2_1$, $Z = 4$, $a = 8.5891(2)$ Å, $b = 16.7819(2)$ Å, $c = 9.8613(1)$ Å, $\beta = 95.8337(13)^\circ$, $V = 1414.06(4)$ Å 3 , $D_x = 1.185$ g cm^{-3} , 5477 unique data ($2\theta_{\text{max}} = 144.6^\circ$), $R = 0.033$ [for 5190 reflections with $I > 2.0\sigma(I)$], $R_w = 0.077$ (all data), $S = 0.99$.

Structure Determinations. Images were measured on a CCD diffractometer (Cu $K\alpha$, mirror monochromator, $\lambda = 1.54184$ Å), and data were extracted using the CrysAlis package.¹⁹ Structure solution was performed using direct methods (SIR92).²⁰ The structures of compounds *ent-2*, *7* (β -epimer), and *14–19* were refined using the CRYSTALS program package.²¹ Atomic coordinates, bond lengths and angles, and displacement parameters for compounds *ent-2*, *7* (β -epimer) and *14–19* have been deposited at the Cambridge Crystallographic Data Centre (CCDC nos. 1442299, 1442300, 1442301, 1442302, 1442303, 1442304, 1442305, and 1442306). These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: + 44 1223 336033.

■ ASSOCIATED CONTENT

📄 Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b00043.

X-ray crystallographic data for compound *ent-2* (CIF)

X-ray crystallographic data for compound *7* (CIF)

X-ray crystallographic data for compound *14* (CIF)

X-ray crystallographic data for compound *15* (CIF)

X-ray crystallographic data for compound *16* (CIF)

X-ray crystallographic data for compound *17* (CIF)

X-ray crystallographic data for compound *18* (CIF)

X-ray crystallographic data for compound *19* (CIF)

^1H and ^{13}C NMR spectra for compounds *ent-1*, *ent-2*, *7* (minor and major epimers), and *8–19* (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: Martin.Banwell@anu.edu.au

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Australian Research Council and the Institute of Advanced Studies for financial support. E.L.C. was the grateful recipient of an Australian Postgraduate Award provided by the Australian Government, and P.L. acknowledges receipt of a CSC Ph.D. Scholarship provided by the Government of the People's Republic of China.

■ REFERENCES

- (1) For a comprehensive review on protoilludanes, see: Siengalewicz, P.; Mulzer, J.; Rinner, U. *Eur. J. Org. Chem.* **2011**, *2011*, 7041.
- (2) For useful points of entry into the literature on the biogenesis of protoilludanes, see: (a) Lackner, G.; Bohnert, B.; Wick, J.; Hoffmeister, D. *Chem. Biol.* **2013**, *20*, 1101. (b) Quin, M. B.; Flynn, C. M.; Schmidt-Dannert, C. *Nat. Prod. Rep.* **2014**, *31*, 1449. (c) Quin, M. B.; Michel, S. N.; Schmidt-Dannert, C. *ChemBioChem* **2015**, *16*, 2191.
- (3) For representative examples of protoilludanes either not listed in the table associated with ref 1 or reported after 2011, see: (a) Fabian, K.; Lorenzen, K.; Anke, T.; Johansson, M.; Sterner, O. *Z. Naturforsch. (C)* **1998**, *53*, 939. (b) Nord, C. L.; Menkis, A.; Vasaitis, R.; Broberg, A. *Phytochemistry* **2013**, *90*, 128. (c) Lou, H.; Zheng, S.; Li, T.; Zhang, J.; Fei, Y.; Hao, X.; Liang, G.; Pan, W. *Org. Lett.* **2014**, *16*, 2696. (d) Nord, C. L.; Menkis, A.; Lendel, C.; Vasaitis, R.; Broberg, A. *Phytochemistry* **2014**, *102*, 197. (e) Yang, X.-Y.; Li, Z.-H.; Dong, Z.-J.; Feng, T.; Liu, J.-K. *J. Asian Nat. Prod. Res.* **2015**, *17*, 1. (f) Kobori, H.; Sekiya, A.; Suzuki, T.; Choi, J.-H.; Hirai, H.; Kawagishi, H. *J. Nat. Prod.* **2015**, *78*, 163.
- (4) For representative and recent studies on the biological activities of protoilludanes, see: (a) Bohnert, M.; Miethbauer, S.; Dahse, H.-M.; Ziemer, J.; Nett, M.; Hoffmeister, D. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2003. (b) Assante, G.; Dallavalle, S.; Anna Martino, P. *J. Antibiot.* **2013**, *66*, 43. (c) Bohnert, M.; Nützmann, H.-W.; Schroeckh, V.; Horn, F.; Dahse, H.-M.; Brakhage, A. A.; Hoffmeister, D. *Phytochemistry* **2014**, *105*, 101.
- (5) (a) Lawrence, A. L.; Lee, V.; Adlington, R. M. *Synlett* **2008**, *2008*, 2087. (b) Schwartz, B. D.; Matoušová, E.; White, R.; Banwell, M. G.; Willis, A. C. *Org. Lett.* **2013**, *15*, 1934. (c) Pitaval, A.; Leboeuf, D.; Cecon, J.; Echavarren, A. M. *Org. Lett.* **2013**, *15*, 4580.
- (6) For pioneering studies in this process, see: (a) Givens, R. S.; Oettle, W. F.; Coffin, R. L.; Carlson, R. G. *J. Am. Chem. Soc.* **1971**, *93*, 3957. (b) Williams, J. R.; Sarkisian, G. M. *J. Chem. Soc. D* **1971**, 1564. (c) Sato, H.; Furutachi, N.; Nakanishi, K. *J. Am. Chem. Soc.* **1972**, *94*, 2150. For a review of the Givens rearrangement and related photochemical processes, see: (d) Banwell, M. G.; Bon, D. J.-Y. D.

Applications of the Di- π -Methane and Related Rearrangement Reactions in Chemical Synthesis. In *Molecular Rearrangements in Organic Synthesis*; Rojas, C. M., Ed.; Wiley: Hoboken, NJ, 2015; Chapter 9, pp 261–288.

(7) For reviews on methods for generating *cis*-1,2-dihydrocatechols by microbial dihydroxylation of the corresponding aromatics, as well as the synthetic applications of these metabolites, see: (a) Hudlicky, T.; Gonzalez, D.; Gibson, D. T. *Aldrichimica Acta* **1999**, *32*, 35. (b) Banwell, M. G.; Edwards, A. J.; Harfoot, G. J.; Jolliffe, K. A.; McLeod, M. D.; McRae, K. J.; Stewart, S. G.; Voegtle, M. *Pure Appl. Chem.* **2003**, *75*, 223. (c) Johnson, R. A. *Org. React.* **2004**, *63*, 117. (d) Hudlicky, T.; Reed, J. W. *Synlett* **2009**, *2009*, 685. (e) Bon, D. J.-Y. D.; Lee, B.; Banwell, M. G.; Cade, I. A. *Chimica Oggi* **2012**, *30*, No. 5 Chiral Technologies Supplement, 22. (f) Rinner, U. Chiral Pool Synthesis: Chiral Pool Syntheses from *cis*-Cyclohexadiene Diols. In *Comprehensive Chirality*; Carreira, E. M., Yamamoto, H., Eds.; Elsevier: Amsterdam, 2012; Vol. 2, p 240. (g) Lewis, S. E. *Chem. Commun.* **2014**, *50*, 2821.

(8) Bon, D. J.-Y. D.; Banwell, M. G.; Willis, A. C. *Tetrahedron* **2010**, *66*, 7807.

(9) Reekie, T. A.; Austin, K. A. B.; Banwell, M. G.; Willis, A. C. *Aust. J. Chem.* **2008**, *61*, 94.

(10) Spiegel, D. A.; Wiberg, K. B.; Schacherer, L. N.; Medeiros, M. R.; Wood, J. L. *J. Am. Chem. Soc.* **2005**, *127*, 12513 and references cited therein.

(11) This protocol is based on one first described by Ma and Bobbitt: Ma, Z.; Bobbitt, J. M. *J. Org. Chem.* **1991**, *56*, 6110.

(12) For examples of related 1,3-acyl migration reactions, see: (a) Singh, V.; Sharma, U. *J. Chem. Soc., Perkin Trans. 1* **1998**, 305. (b) Banwell, M. G.; Harfoot, G. J. *Aust. J. Chem.* **2004**, *57*, 895. (c) Lan, P.; Banwell, M. G.; Willis, A. C. *Org. Lett.* **2015**, *17*, 166.

(13) Taber, D. F.; DeMatteo, P. W.; Hassan, R. A. *Org. Synth.* **2014**, *90*, 350.

(14) Gilman, H.; Jones, R. G.; Woods, L. A. *J. Org. Chem.* **1952**, *17*, 1630.

(15) The formation of dimer **18** from monomer **16** reported here has strong similarities to a dimerization process reported in ref **12b**. For examples of related dimerizations involving 4-hydroxy-2-cyclohexen-1-ones, see: (a) Paddock, V. L.; Phipps, R. J.; Conde-Angulo, A.; Blanco-Martin, A.; Giró-Mañas, C.; Martin, L. J.; White, A. J. P.; Spivey, A. C. *J. Org. Chem.* **2011**, *76*, 1483. (b) Palframan, M. J.; Kociok-Köhn, G.; Lewis, S. E. *Chem. - Eur. J.* **2012**, *18*, 4766.

(16) For the application of this type of enantiomeric switching regime to the synthesis of other classes of natural products, see: (a) Austin, K. A. B.; Elsworth, J. D.; Banwell, M. G.; Willis, A. C. *Org. Biomol. Chem.* **2010**, *8*, 751. (b) Dietinger, C. E.; Banwell, M. G.; Garson, M. J.; Willis, A. C. *Tetrahedron* **2010**, *66*, 5250.

(17) Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* **1978**, *43*, 2923.

(18) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. *Organometallics* **1996**, *15*, 1518.

(19) CrysAlis PRO, version 1.171.37.35h (release 09–02–2015 CrysAlis171.NET) (compiled Feb 9 2015,16:26:32); Agilent Technologies: Oxfordshire, U.K., 2015.

(20) Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Burla, M. C.; Polidori, G.; Camalli, M. *SIR92. J. Appl. Crystallogr.* **1994**, *27*, 435.

(21) Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.; Watkin, D. J. *J. Appl. Crystallogr.* **2003**, *36*, 1487.